Merck & Co., Inc. $MRK Shares Purchased by Eldred Rock Partners LLC

Eldred Rock Partners LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 6.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,413 shares of the company’s stock after acquiring an additional 7,161 shares during the period. Merck & Co., Inc. accounts for about 3.2% of Eldred Rock Partners LLC’s holdings, making the stock its 15th biggest position. Eldred Rock Partners LLC’s holdings in Merck & Co., Inc. were worth $14,959,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. State Street Corp raised its stake in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, Morgan Stanley grew its position in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock valued at $4,731,018,000 after buying an additional 359,486 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MRK shares. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Barclays boosted their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Bank of America lifted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.56.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $128.61 on Friday. The firm has a market capitalization of $317.64 billion, a price-to-earnings ratio of 102.89, a price-to-earnings-growth ratio of 5.53 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business’s 50 day simple moving average is $123.98 and its 200-day simple moving average is $119.11. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 86,553 shares of company stock worth $11,177,945. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.